Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionDEUTSCHE DWS INVESTMENTS VIT FUNDS - DWS Small Cap Index VIP Class A
Latest Disclosed Ownership16,282 shares
Latest Disclosed Value $ 403,142
DEUTSCHE DWS INVESTMENTS VIT FUNDS - DWS Small Cap Index VIP Class A reports 4.15% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 28, 2026 - DEUTSCHE DWS INVESTMENTS VIT FUNDS - DWS Small Cap Index VIP Class A filed a NPORT-P form disclosing ownership of 16,282 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $403,142 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 26, 2026 disclosing 16,987 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -4.15% during the quarter. The current value of the position is $512,720 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-28 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,282 -705 -4.15 403 1.77 0.0962
2026-02-26 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,987 -574 -3.27 396 14.78 0.0914
2025-11-26 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 17,561 -188 -1.06 346 -10.39 0.0787
2025-08-22 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 17,749 796 4.70 385 -6.33 0.0968
2025-05-22 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,953 -505 -2.89 411 12.91 0.1110
2025-02-27 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 17,458 -327 -1.84 364 3.12 0.0863
2024-11-22 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 17,785 1,145 6.88 354 37.35 0.0822
2024-08-26 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 16,640 312 1.91 258 -1.15 0.0658
2024-05-28 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,328 890 5.76 260 0.39 0.0644
2024-02-27 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 15,438 564 3.79 260 49.71 0.0659
2023-11-17 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 14,874 -255 -1.69 174 -14.78 0.0508
2023-08-23 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,129 308 2.08 203 -17.14 0.0538
2023-05-26 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 14,821 0 0.00 246 -10.91 0.0672
2023-02-28 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 14,821 508 3.55 276 50.27 0.0759
2022-11-25 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 14,313 0 0.00 184 83.00 0.0551
2022-08-26 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 14,313 0 0.00 100 -15.25 0.0295
2022-05-24 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 14,313 -883 -5.81 119 15.69 0.0285
2022-02-25 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 15,196 0 0.00 103 27.50 0.0220
2021-11-19 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,196 0 0.00 81 -8.05 0.0177
2021-08-27 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 15,196 -1,568 -9.35 87 12.99 0.0184
2021-05-26 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,764 0 0.00 77 40.00 0.0166
2021-02-24 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 16,764 0 0.00 56 12.24 0.0132
2020-11-23 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 16,764 -1,515 -8.29 50 -41.67 0.0149
2020-08-26 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 18,279 1,064 6.18 84 27.27 0.0250
2020-05-27 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 17,215 0 0.00 66 3.13 0.0256
2020-02-27 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 17,215 0 0.00 65 -29.67 0.0167
2019-11-26 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 17,215 17,215 91 0.0259
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.